Radioimmunotherapy of DU-145 tumours in nude mice - A pilot study with E4, a novel monoclonal antibody against prostate cancer

Acta Oncologica

Volumn 38, Issue 8, 1999, Pages 1075-1079

  Rydh, Anders ^a   Riklund Åhlström, Katrine ^a   Widmark, Anders ^a   Bergh, Anders ^a   Johansson, Lennart ^a   Tavelin, Björn ^a   Nilsson, Sten ^b   Stigbrand, Torgny ^a   Damber, Jan Erik ^a   Hietala, Sven Ola ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROMAB PENDETIDE IN 111; LEXIDRONAM SAMARIUM SM 153; METASTRONE; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; STRONTIUM 89; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; GENETIC POLYMORPHISM; ISOTOPE LABELING; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOIMMUNOTHERAPY; XENOGRAFT;

EID: 0033451494     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699432392     Document Type: Article

References (26)

1. Grönberg H, Bergh A, Damber JE, Jonnson H, Lenner P, Ångström T. Prostate cancer in northern Sweden. Incidence, survival and mortality in relation to tumour grade. Acta Oncol 1994; 33: 359-63.
2. Mettlin CJ, Murphy GP, Ho R, Menck HR. The national cancer database report on longitudinal observations on prostate cancer. Cancer 1996; 77: 2162-6.
3. Prostatacancer Primärregistrering 1996. Regional Centre of Oncology, Akademiska sjukhuset, Uppsala, Sweden. (In Swedish).
4. Crawford ED, Kozlowski JM, Debruyne FMG, et al. The use of Strontium-89 for palliation of pain from bone metastases associated with hormone refractory prostate cancer. Urol 1994; 44: 481-5.
5. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574-81.
6. Goethuys H, Baert L, Van Poppel H, Lieskovsky G, Brady LW, Petrovich Z. Treatment of metastatic carcinoma of the prostate. Am J Clin Oncol 1997; 20: 40-5.
7. Boyle P, Maisonneuve P, Napalkov P. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urol 1995; 46: 47-55.
8. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
9. Neal CE, Meis LC. Correlative imaging with monoclonal antibodies in colorectal, ovarian and prostate cancer. Semin Nucl Med 1994; XXIV: 272-85.
10. Park CH. The role of radioisotopes in radiation oncology. Semin Oncol 1997; 24: 639-54.
11. Burgers JK, Hinkle GH, Haseman MK. Monoclonal anti-body imaging of recurrent and metastatic prostate cancer. Semin Urol 1995; XIII: 103-12.
12. Babaian RJ, Sayer J, Podoloff DA, Steelhammer LC, Bhadamkar VA, Gulfo JVV. Radioimmunoscintigraphy of pelvic lymph nodes with III-Indium-labeled monoclonal anti-body CYT-356. J Urol 1994; 152: 1952-5.
13. Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med 1993; 94: 297-312.
14. Goldenberg D. Cancer therapy with radiolabeled antibodies. Boca Raton, FL: CRC Press, 1995.
15. 131-labelled monoclonal antibodies against placental alkaline phosphatase and cytokeratin. Tumor Targeting 1995; 1: 239-44.
16. Jurcic JG, Scheinberg DA, Houghton AN. Monoclonal anti-body therapy of cancer. In: Pinedo HM, Longo DL, Chabner BA, eds. Cancer chemotherapy and biological response modifiers, Annual 17. Amsterdam: Elsevier, 1997: 195-216.
17. Rossi Norrlund R. Improving experimental tumor radioimmunotargeting. Thesis, Sweden: Umeå University, 1997.
18. Rydh A, Riklund Åhlström K, Widmark A, Johansson L, Nilsson S, Bergh A, Damber JE, Stigbrand T, Hietala SO. Radioimmunoscintigraphy with a novel monoclonal antiprostate antibody (E4). Cancer 1997; 80 (Suppl): 2398-403.
19. Essand M. Radioimmunotargeting of cancer cells: studies on prostatic adenocarcinoma spheroids and characterization of a novel monoclonal anti-prostate antibody. Thesis. Sweden: Uppsala University, 1995.
20. Greenwood FC, Hunter WM, Glover JS. The preparation of 131-I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114-23.
21. Carlsson L, Sottrup-Jensen L, Stigbrand T. A two-site monoclonal enzyme immunoassay for pregnancy-associated alfa 2-glycoprotein. J Immunol Methods 1987; 104: 73-9.
22. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU145). Int J Cancer 1978; 21: 274-81.
23. Weibel ER. Stereological methods, vol 1. Practical methods for biological morphometry. New York: Academic Press, 1980.
24. Stattin P, Damber JE, Karlberg L, Bergh A. Cell proliferation assessed by KI-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 1997; 157: 219-22.
25. Nias AHW. An introduction to radiobiology. 2nd ed. Wiley, 1998: 206.
26. 131I-labeled monoclonal antibody Nd2 in xenografted nude mice. Jpn J Cancer Res 1996; 87: 977-84.